Microlife Wrist Watch Blood Pressure Monitor, Model BP3MK1-3 (BP W100)
510(k) K073398
Active
Valid until
No expiry
FDA recalls
None foundDocuments
Trust
Unverified
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK073398 | Date20 Dec 2007 | StatusActive |
Recalls
No FDA recalls found in the data synced 22 Oct 2026.
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k) Active
Specification
- 510(k) Number
- FDA Product Code
- DXN
- Device Class
- Class II
- Regulation
- 21 CFR Part 870.1130
- Advisory Committee
- Cardiovascular
- FDA Decision
- SESE Substantially Equivalent
Overview
AI-generated summary, 23 Sep 2026
This device is a wrist-worn blood pressure monitor designed for measuring blood pressure. It is identified as the Microlife Wrist Watch Blood Pressure Monitor, Model BP3MK1-3 (BP W100).
It is supplied as a consumer medical device for home use and has received FDA 510(k) clearance under product code DXN. The device was determined to be substantially equivalent to a predicate device, with clearance granted on December 20, 2007, under special 510(k) review by the Cardiovascular advisory committee.
Other devices from Microlife Corp.
Questions
AI-generated answers, 23 Sep 2026
What is the Microlife Wrist Watch Blood Pressure Monitor BP3MK1-3 used for?
This device is designed for measuring blood pressure in a home setting. It is worn on the wrist and provides blood pressure readings for personal health monitoring, as stated in its description as a consumer medical device for home use.
How is the Microlife BP3MK1-3 supplied and is it reusable?
The device is supplied as a consumer medical device for home use. It is intended for repeated personal use by an individual, as it is a wearable monitor designed for ongoing home blood pressure tracking, not as a single-use disposable product.
What regulatory pathway was used for the Microlife BP3MK1-3 and when was it cleared?
The device received FDA 510(k) clearance under product code DXN, determined to be substantially equivalent to a predicate device. Clearance was granted on December 20, 2007, following a special 510(k) review by the Cardiovascular advisory committee.